Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax Covid Vaccine On the Verge of Approval in Japan, Reports Nikkei Asia

Published 04/18/2022, 02:23 PM
Updated 04/18/2022, 02:27 PM
© Reuters

© Reuters

By Sam Boughedda

Investing.com -- Novavax Inc's (NASDAQ:NVAX) Covid-19 vaccine has been cleared for approval by a Japanese government panel, according to Nikkei Asia.

The Novavax vaccine will become Japan's fourth vaccine option, reported Nikkei's Daishi Chiba.

Before shots can be administered, the vaccine will need to be approved by a separate expert committee within the health ministry. If it gets the go-ahead, it will be available to people 18 and over and can be used for the first two shots, as well as booster jabs.

Novavax has already contracted Takeda Pharmaceuticals to manufacture and distribute the vaccine in Japan. 

Shares of Novavax dipped 5.5% Monday despite the news, adding to its significant decline in 2022. However, it clawed back some of its losses from earlier in the session following the report. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.